An increasing number of studies have demonstrated that immunotherapy has a considerable role in the treatment of BLCA, especially for the use of immune checkpoint (PD-1, PD-L1, and CTLA-4) inhibitors (19–22). Here, CD274 is linked to bladder transitional cell carcinoma.